Mohammad Nafeli Shahrestani: CXCL10 Associated With Increased Long-Term Risk of Ischemic Stroke
Mohammad Nafeli Shahrestani, Postdoctoral Research Fellow at University of Miami Evelyn F. McKnight Brain Institute, Medical Doctor at Private Practice, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Translational Stroke Research, adding:
“I’m glad to share that our new article has been published in Translational Stroke Research. We performed a large-scale but immune-focused screening of plasma immune markers in the Northern Manhattan Study (NOMAS).
Machine learning-assisted data reduction identified C-X-C motif chemokines as candidate markers of stroke risk. One standard deviation (SD) increase in baseline plasma C-X-C motif chemokine ligand 10 (CXCL10) was associated with a 20% greater risk of all-cause and ischemic stroke over more than a decade of follow-up.
This association was independent of sociodemographic factors, cardiovascular risk factors, comorbidities, MRI-measured white matter disease, and kidney function. The results were internally validated.
CXCL10, a chemokine induced by interferon gamma (IFN-γ), may play a direct role in stroke pathogenesis.
Our findings suggest that CXCL10 is a marker of cerebrovascular disease and may add prognostic value when integrated with clinical, imaging, and laboratory assessments. CXCL10 may also be a target for pharmacological intervention to preserve cerebrovascular health.
I am grateful to all NOMAS participants, my mentors, and my co-authors.”
Title: Chemokine CXCL10 and Incident Stroke Risk in the Northern Manhattan Study
Authors: Mohammad Nafeli Shahrestani, Christian Agudelo, Hannah Gardener, Emir Veledar, Jose A Santiago, Marco R Di Tullio, David Della-Morte, Botagoz Aimagambetova, Jose Gutierrez, Mady Hornig, Mitchell S V Elkind, Hyun Song, Clinton B Wright, Sarah E Tom, Tatjana Rundek
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 4, 2026, 02:46Arman Qamar: Drug-Coated Balloons in Coronary Bifurcation PCI
-
Oct 4, 2026, 01:13Francesc Formiga: Updated Evidence on LAA Closure Versus Oral Anticoagulation in AF
-
Oct 4, 2026, 01:11Alicja Urbaniak: Targeting CD148 to Develop New Antithrombotic Therapies
-
Oct 4, 2026, 01:03Susan Mou: Presenting Long-Term Clinical Outcomes in SCD and TDT
-
Oct 4, 2026, 01:00Mark Johnson: Elevating Patient and Warrior Voices During Sickle Cell Awareness Month
-
Oct 4, 2026, 00:55Pier Maria Fornasari: Possible New Target for SCD and Beta Thalassemia Treatment
-
Oct 4, 2026, 00:48Sthanu Subramanian: Mechanisms, Clinical Phenotypes, Imaging, and Treatment of CVT
-
Oct 4, 2026, 00:33Ashish Pemawat: Can We Protect the Brain while We Restore Blood Flow?
-
Oct 4, 2026, 00:32Marta Nowakowska-Kotas: Could a Small Rise in Creatinine after Thrombectomy in Stroke Patients Be an Early Warning Sign?